<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373098</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720DTR04</org_study_id>
    <nct_id>NCT02373098</nct_id>
  </id_info>
  <brief_title>Fingolimod Effect on Cytokine and Chemokine Levels</brief_title>
  <official_title>Effects of Fingolimod (GilenyaÂ®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to measure the serum levels of cytokines and chemokines
      that are known to increase during multiple sclerosis relapses.

      Cytokines are a broad and loose category of small proteins that are important in cell
      signaling.

      The second purpose of the study was to test the cytokine/chemokine changes measured in the
      3rd and 6th months on the efficacy parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Actual">January 18, 2017</completion_date>
  <primary_completion_date type="Actual">January 18, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A 6-month, multicenter, prospective, interventional, single arm, open label study investigating the effects of fingolimod administered according to local label recommendations on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood samples were taken at baseline and measurements were performed before treatment of fingolimod.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Flow Cytometry Analyses for Blood Cytokines and Chemokines in Healthy Controls and RRMS Patients</measure>
    <time_frame>Baseline</time_frame>
    <description>baseline peripheral blood flow cytometric analysis in study participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Blood Cytokines and Chemokines Via Flow Cytometry Analyses of Healthy Controls and RRMS Patients at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline peripheral blood flow cytometric analyses in study participants evaluated by flow cytometry analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Cytokine and Chemokine Levels inRRMS Patients Between Visits</measure>
    <time_frame>Baseline, month 3, month 6</time_frame>
    <description>Change of serum cytokine and chemokine levels measured by ELISA in RRMS patients treated with fingolimod between visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <description>Peripheral blood chemokine cytokine levels measured by flow cytometry during fingolimod treatment in healthy controls at baseline and in RRMS patients between visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <description>Peripheral blood chemokine cytokine levels measured by flow cytometry at baseline and between visits during fingolimod treatment.
Absolute counts of the cells were calculated according to the absolute lymphocyte counts and the percentages of cells. This allowed for a clear determination of cell counts and thus increased the reliability of the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <description>Peripheral blood chemokine cytokine levels measured by flow cytometry in healthy controls at baseline and in RRMS patients between visits during fingolimod treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>FTY720</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy volunteers with no intervention or drug administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 0.5 mg</intervention_name>
    <description>66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.</description>
    <arm_group_label>FTY720</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Written informed consent must be obtained before the beginning of te study

          2. Nonresponder RRMS patients

          3. Last relapse of the patient should be at least 2 months before study entry.

          4. Last interferon or glatiramer acetate dose of the patient should be at least 1 month
             before study entry.

        Key Exclusion Criteria:

          1. Patients with secondary progressive MS.

          2. Patients with known contraindications for fingolimod treatment.

          3. Other coexistent autoimmune diseases

          4. Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mecidiyekoy</city>
        <state>Istanbul</state>
        <zip>34394</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uskudar</city>
        <state>Istanbul</state>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>October 4, 2018</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2019</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fingolimod,cytokine,chemokine,RRMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02373098/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02373098/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>60 healthy controls and 66 Relapsing-remitting multiple sclerosis (RRMS) patients were enrolled in the study. The healthy volunteers had only Visit 1 (Day 0). Fingolimod 0.5 mg capsule once daily was given on the same day to RRMS patients. Patients were treated for 6 months with 2 additional visits, Visit 2 and Visit 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FTY720</title>
          <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Volunteers</title>
          <description>The healthy volunteers had only Visit 1 (Day 0) and served as control group for cytokine/chemokine measurements</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set</population>
      <group_list>
        <group group_id="B1">
          <title>FTY720</title>
          <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Volunteers</title>
          <description>The healthy volunteers had only Visit 1 (Day 0) and served as control group for cytokine/chemokine measurements</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.75" spread="8.20"/>
                    <measurement group_id="B2" value="34.73" spread="9.62"/>
                    <measurement group_id="B3" value="35.27" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Turkish</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA</title>
        <description>Blood samples were taken at baseline and measurements were performed before treatment of fingolimod.</description>
        <time_frame>Baseline</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy volunteers had only Visit 1 (day 0) when serum and whole blood samples were taken.</description>
          </group>
          <group group_id="O2">
            <title>FTY720</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA</title>
          <description>Blood samples were taken at baseline and measurements were performed before treatment of fingolimod.</description>
          <population>Intent to treat</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCL5 (RANTES)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.26" spread="22.48"/>
                    <measurement group_id="O2" value="404.31" spread="55.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.03"/>
                    <measurement group_id="O2" value="1.06" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.8" spread="22.3"/>
                    <measurement group_id="O2" value="139.68" spread="46.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.324"/>
                    <measurement group_id="O2" value="66.53" spread="65.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.47"/>
                    <measurement group_id="O2" value="3.57" spread="0.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.331"/>
                    <measurement group_id="O2" value="0.3" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.552"/>
                    <measurement group_id="O2" value="3.04" spread="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLA4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.396"/>
                    <measurement group_id="O2" value="0.58" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10=IP-10 (CXCR3 ligand)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.09" spread="1.76"/>
                    <measurement group_id="O2" value="18.18" spread="2.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCL2=MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.88" spread="4.281"/>
                    <measurement group_id="O2" value="62.89" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.077"/>
                    <measurement group_id="O2" value="2.36" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.195"/>
                    <measurement group_id="O2" value="1.06" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.36" spread="0.581"/>
                    <measurement group_id="O2" value="22.41" spread="0.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCL5=RANTES</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL17A</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CXCL13</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.934</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL13</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.727</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL23</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VLA4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CXCL10=IP-10 (CXCR3 ligand)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.730</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CCL2=MCP-1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.725</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TNF alpha</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL22</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Flow Cytometry Analyses for Blood Cytokines and Chemokines in Healthy Controls and RRMS Patients</title>
        <description>baseline peripheral blood flow cytometric analysis in study participants</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis was done in the healthy volunteers and RRMS patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy volunteers had only Visit 1 (day 0) when serum and whole blood samples were taken.</description>
          </group>
          <group group_id="O2">
            <title>FTY720</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Flow Cytometry Analyses for Blood Cytokines and Chemokines in Healthy Controls and RRMS Patients</title>
          <description>baseline peripheral blood flow cytometric analysis in study participants</description>
          <population>Analysis was done in the healthy volunteers and RRMS patients.</population>
          <units>absolute cell count</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3 abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2048.14" spread="263.209"/>
                    <measurement group_id="O2" value="1610.94" spread="126.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19 abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.63" spread="57.592"/>
                    <measurement group_id="O2" value="327.63" spread="44.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.33" spread="39.106"/>
                    <measurement group_id="O2" value="623.57" spread="394.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NKT abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.86" spread="16.627"/>
                    <measurement group_id="O2" value="104.36" spread="15.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hi CD16CD56 abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.64" spread="4.399"/>
                    <measurement group_id="O2" value="20.44" spread="3.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4CD25 (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.08" spread="3.159"/>
                    <measurement group_id="O2" value="27.08" spread="1.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hi CD4CD25 (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="0.383"/>
                    <measurement group_id="O2" value="3.33" spread="0.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3 abs</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.256</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD19 abs</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NK abs</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.300</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NKT abs</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hi CD16CD56 abs</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.270</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4CD25</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.902</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hi CD4CD25</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.283</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Cytokine and Chemokine Levels inRRMS Patients Between Visits</title>
        <description>Change of serum cytokine and chemokine levels measured by ELISA in RRMS patients treated with fingolimod between visits</description>
        <time_frame>Baseline, month 3, month 6</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Visit 1</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 1</description>
          </group>
          <group group_id="O2">
            <title>Visit 2</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 2</description>
          </group>
          <group group_id="O3">
            <title>Visit 3</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cytokine and Chemokine Levels inRRMS Patients Between Visits</title>
          <description>Change of serum cytokine and chemokine levels measured by ELISA in RRMS patients treated with fingolimod between visits</description>
          <population>Intent to treat</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CXCL13=BLC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.68" spread="46.631"/>
                    <measurement group_id="O2" value="105.42" spread="20.61"/>
                    <measurement group_id="O3" value="105.86" spread="22.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.53" spread="65.411"/>
                    <measurement group_id="O2" value="49.98" spread="49.263"/>
                    <measurement group_id="O3" value="149.62" spread="144.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.553"/>
                    <measurement group_id="O2" value="3.84" spread="0.482"/>
                    <measurement group_id="O3" value="4.29" spread="0.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.15"/>
                    <measurement group_id="O2" value="0.35" spread="0.208"/>
                    <measurement group_id="O3" value="0.48" spread="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCL5= RANTES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.31" spread="55.189"/>
                    <measurement group_id="O2" value="384.12" spread="52.649"/>
                    <measurement group_id="O3" value="480.34" spread="63.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="0.924"/>
                    <measurement group_id="O2" value="2.01" spread="0.629"/>
                    <measurement group_id="O3" value="2.15" spread="0.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLA4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.201"/>
                    <measurement group_id="O2" value="0.76" spread="0.356"/>
                    <measurement group_id="O3" value="0.82" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXCL10=IP-10 (CXCR3 ligand)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" spread="2.405"/>
                    <measurement group_id="O2" value="18.46" spread="2.356"/>
                    <measurement group_id="O3" value="20.54" spread="3.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCL2=MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.89" spread="8.42"/>
                    <measurement group_id="O2" value="74.38" spread="10.011"/>
                    <measurement group_id="O3" value="92.73" spread="13.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.149"/>
                    <measurement group_id="O2" value="1.94" spread="0.099"/>
                    <measurement group_id="O3" value="2.12" spread="0.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.029"/>
                    <measurement group_id="O2" value="1.09" spread="0.04"/>
                    <measurement group_id="O3" value="1.04" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.1"/>
                    <measurement group_id="O2" value="1.26" spread="0.196"/>
                    <measurement group_id="O3" value="1.12" spread="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.41" spread="0.69"/>
                    <measurement group_id="O2" value="22.45" spread="0.843"/>
                    <measurement group_id="O3" value="22.99" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</title>
        <description>Peripheral blood chemokine cytokine levels measured by flow cytometry during fingolimod treatment in healthy controls at baseline and in RRMS patients between visits</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <population>Intent to treat. Data analyzed in RRMS patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy volunteers had only Visit 1 (day 0) when serum and whole blood samples were taken.</description>
          </group>
          <group group_id="O2">
            <title>Visit 1</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 1</description>
          </group>
          <group group_id="O3">
            <title>Visit 2</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 2</description>
          </group>
          <group group_id="O4">
            <title>Visit 3</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</title>
          <description>Peripheral blood chemokine cytokine levels measured by flow cytometry during fingolimod treatment in healthy controls at baseline and in RRMS patients between visits</description>
          <population>Intent to treat. Data analyzed in RRMS patients.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3 abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2048.14" spread="263.209"/>
                    <measurement group_id="O2" value="1610.94" spread="126.071"/>
                    <measurement group_id="O3" value="339.74" spread="43.44"/>
                    <measurement group_id="O4" value="314.75" spread="30.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19 abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.63" spread="57.592"/>
                    <measurement group_id="O2" value="327.63" spread="44.421"/>
                    <measurement group_id="O3" value="32.9" spread="5.347"/>
                    <measurement group_id="O4" value="26.56" spread="2.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.33" spread="39.106"/>
                    <measurement group_id="O2" value="623.57" spread="394.837"/>
                    <measurement group_id="O3" value="203.66" spread="30.487"/>
                    <measurement group_id="O4" value="181.97" spread="20.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NKT abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.86" spread="16.627"/>
                    <measurement group_id="O2" value="104.36" spread="15.08"/>
                    <measurement group_id="O3" value="88.45" spread="12.725"/>
                    <measurement group_id="O4" value="88.98" spread="11.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hi CD16CD56 abs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.64" spread="4.399"/>
                    <measurement group_id="O2" value="20.44" spread="3.506"/>
                    <measurement group_id="O3" value="29.35" spread="8.73"/>
                    <measurement group_id="O4" value="30.04" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4CD25 (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.08" spread="3.159"/>
                    <measurement group_id="O2" value="27.03" spread="1.251"/>
                    <measurement group_id="O3" value="9.24" spread="1.407"/>
                    <measurement group_id="O4" value="9.22" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hi CD4CD25 (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="0.383"/>
                    <measurement group_id="O2" value="3.33" spread="0.253"/>
                    <measurement group_id="O3" value="2.03" spread="0.302"/>
                    <measurement group_id="O4" value="1.77" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Blood Cytokines and Chemokines Via Flow Cytometry Analyses of Healthy Controls and RRMS Patients at Baseline</title>
        <description>Baseline peripheral blood flow cytometric analyses in study participants evaluated by flow cytometry analysis.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis was done in the healthy volunteers and RRMS patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy volunteers had only Visit 1 (day 0) when serum and whole blood samples were taken.</description>
          </group>
          <group group_id="O2">
            <title>FTY720</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Blood Cytokines and Chemokines Via Flow Cytometry Analyses of Healthy Controls and RRMS Patients at Baseline</title>
          <description>Baseline peripheral blood flow cytometric analyses in study participants evaluated by flow cytometry analysis.</description>
          <population>Analysis was done in the healthy volunteers and RRMS patients.</population>
          <units>Percent of cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.52" spread="1.494"/>
                    <measurement group_id="O2" value="71.92" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="1.018"/>
                    <measurement group_id="O2" value="13.72" spread="1.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.04" spread="1.328"/>
                    <measurement group_id="O2" value="10.17" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NKT %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="0.855"/>
                    <measurement group_id="O2" value="5.19" spread="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hi CD16CD56 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.183"/>
                    <measurement group_id="O2" value="0.93" spread="0.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD4 % (Lymphogate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.19" spread="2.483"/>
                    <measurement group_id="O2" value="44.91" spread="1.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD8 % (Lymphogate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.23" spread="2.175"/>
                    <measurement group_id="O2" value="22.91" spread="1.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD4 % (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.38" spread="2.722"/>
                    <measurement group_id="O2" value="62.99" spread="1.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD8 % (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.11" spread="2.305"/>
                    <measurement group_id="O2" value="31.20" spread="1.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IFNg+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="1.994"/>
                    <measurement group_id="O2" value="3.61" spread="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL17+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.173"/>
                    <measurement group_id="O2" value="1.27" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IFNg+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.45" spread="3.896"/>
                    <measurement group_id="O2" value="5.47" spread="2.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL17+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.636"/>
                    <measurement group_id="O2" value="4.20" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="1.896"/>
                    <measurement group_id="O2" value="1.98" spread="0.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL17+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.264"/>
                    <measurement group_id="O2" value="2.06" spread="0.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL10+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.33"/>
                    <measurement group_id="O2" value="0.72" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL4+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.294"/>
                    <measurement group_id="O2" value="0.96" spread="0.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD8-IL4+ (in CD4-CD8-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.31"/>
                    <measurement group_id="O2" value="2.62" spread="1.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL10+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.089"/>
                    <measurement group_id="O2" value="0.31" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL4+ % (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="3.74"/>
                    <measurement group_id="O2" value="1.87" spread="0.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL10+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.228"/>
                    <measurement group_id="O2" value="1.81" spread="0.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL4+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.34"/>
                    <measurement group_id="O2" value="0.50" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+TNFa+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86" spread="4.892"/>
                    <measurement group_id="O2" value="23.72" spread="4.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL9+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.109"/>
                    <measurement group_id="O2" value="0.54" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+TNFa+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="4.876"/>
                    <measurement group_id="O2" value="11.78" spread="2.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL9+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.087"/>
                    <measurement group_id="O2" value="0.90" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.82" spread="5.019"/>
                    <measurement group_id="O2" value="23.29" spread="4.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL9+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="4.497"/>
                    <measurement group_id="O2" value="0.59" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3 %</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD19 %</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.300</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NK %</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.657</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NKT %</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.439</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hi CD16CD56 %</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3CD4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3CD8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.787</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3CD4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.121</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3CD8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.209</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4+IFNg+ (in CD4+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4+IL17+ (in CD4+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.402</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD8+IFNg+ (in CD8+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD8+IL17+ (in CD8+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IFNg+ (in CD4+CD25+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL17+ (in CD4+CD25+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4+IL10+ (in CD4+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4+IL4+ (in CD4+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4-CD8-IL4+ (in CD4-CD8-)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.171</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD8+IL10+ (in CD8+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD8+IL4+ (in CD8+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL10+ (in CD4+CD25+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL4+ (in CD4+CD25+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4+TNFa+ (in CD4+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD4+IL9+ (in CD4+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD8+TNFa+ (in CD8+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD8+IL9+ (in CD8+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TNFa+ (in CD4+CD25+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL9+ (in CD4+CD25+)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</title>
        <description>Peripheral blood chemokine cytokine levels measured by flow cytometry at baseline and between visits during fingolimod treatment.
Absolute counts of the cells were calculated according to the absolute lymphocyte counts and the percentages of cells. This allowed for a clear determination of cell counts and thus increased the reliability of the results.</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <population>Intent to treat. Data analyzed in RRMS patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy volunteers had only Visit 1 (day 0) when serum and whole blood samples were taken.</description>
          </group>
          <group group_id="O2">
            <title>Visit 1</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 1</description>
          </group>
          <group group_id="O3">
            <title>Visit 2</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 2</description>
          </group>
          <group group_id="O4">
            <title>Visit 3</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</title>
          <description>Peripheral blood chemokine cytokine levels measured by flow cytometry at baseline and between visits during fingolimod treatment.
Absolute counts of the cells were calculated according to the absolute lymphocyte counts and the percentages of cells. This allowed for a clear determination of cell counts and thus increased the reliability of the results.</description>
          <population>Intent to treat. Data analyzed in RRMS patients.</population>
          <units>absolute cell count</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3CD4 (Lymphogate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.19" spread="2.483"/>
                    <measurement group_id="O2" value="44.91" spread="1.321"/>
                    <measurement group_id="O3" value="13.64" spread="1.712"/>
                    <measurement group_id="O4" value="13.9" spread="1.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD8 (Lymphogate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.23" spread="2.175"/>
                    <measurement group_id="O2" value="22.91" spread="1.188"/>
                    <measurement group_id="O3" value="32.93" spread="1.967"/>
                    <measurement group_id="O4" value="32.22" spread="2.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD4 (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.38" spread="2.722"/>
                    <measurement group_id="O2" value="62.99" spread="1.446"/>
                    <measurement group_id="O3" value="23.26" spread="2.726"/>
                    <measurement group_id="O4" value="24" spread="2.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3CD8 (CD3 gate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.11" spread="2.305"/>
                    <measurement group_id="O2" value="31.2" spread="1.351"/>
                    <measurement group_id="O3" value="59.52" spread="2.534"/>
                    <measurement group_id="O4" value="59.66" spread="2.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IFNg+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="1.994"/>
                    <measurement group_id="O2" value="3.61" spread="1.037"/>
                    <measurement group_id="O3" value="7.85" spread="2.197"/>
                    <measurement group_id="O4" value="13.97" spread="2.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL17+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.173"/>
                    <measurement group_id="O2" value="1.27" spread="0.298"/>
                    <measurement group_id="O3" value="1.26" spread="0.224"/>
                    <measurement group_id="O4" value="2.02" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IFNg+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.45" spread="3.896"/>
                    <measurement group_id="O2" value="5.47" spread="2.463"/>
                    <measurement group_id="O3" value="5.73" spread="1.968"/>
                    <measurement group_id="O4" value="14.7" spread="3.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL17+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.636"/>
                    <measurement group_id="O2" value="4.2" spread="0.923"/>
                    <measurement group_id="O3" value="9.22" spread="3.105"/>
                    <measurement group_id="O4" value="2.23" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="1.896"/>
                    <measurement group_id="O2" value="1.98" spread="0.469"/>
                    <measurement group_id="O3" value="7.07" spread="1.719"/>
                    <measurement group_id="O4" value="9.31" spread="1.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL17+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.264"/>
                    <measurement group_id="O2" value="2.06" spread="0.41"/>
                    <measurement group_id="O3" value="1.85" spread="0.31"/>
                    <measurement group_id="O4" value="2.7" spread="0.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL10+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.33"/>
                    <measurement group_id="O2" value="0.72" spread="0.196"/>
                    <measurement group_id="O3" value="1.51" spread="0.422"/>
                    <measurement group_id="O4" value="2.14" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL4+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="2.94"/>
                    <measurement group_id="O2" value="0.96" spread="0.41"/>
                    <measurement group_id="O3" value="1.45" spread="0.294"/>
                    <measurement group_id="O4" value="2.32" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD8-IL4+ (in CD4-CD8-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.31"/>
                    <measurement group_id="O2" value="2.62" spread="1.125"/>
                    <measurement group_id="O3" value="1.77" spread="0.267"/>
                    <measurement group_id="O4" value="2.64" spread="0.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL10+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.089"/>
                    <measurement group_id="O2" value="0.31" spread="0.096"/>
                    <measurement group_id="O3" value="0.25" spread="0.107"/>
                    <measurement group_id="O4" value="0.67" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL10+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.228"/>
                    <measurement group_id="O2" value="1.81" spread="0.464"/>
                    <measurement group_id="O3" value="2.88" spread="0.471"/>
                    <measurement group_id="O4" value="4.03" spread="0.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL4+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.34"/>
                    <measurement group_id="O2" value="0.5" spread="0.105"/>
                    <measurement group_id="O3" value="1.22" spread="0.224"/>
                    <measurement group_id="O4" value="1.49" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+TNFa+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86" spread="4.892"/>
                    <measurement group_id="O2" value="23.72" spread="4.707"/>
                    <measurement group_id="O3" value="29.45" spread="5.681"/>
                    <measurement group_id="O4" value="49.96" spread="5.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+IL9+ (in CD4+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.109"/>
                    <measurement group_id="O2" value="0.54" spread="0.163"/>
                    <measurement group_id="O3" value="0.4" spread="0.098"/>
                    <measurement group_id="O4" value="0.47" spread="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+TNFa+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="4.876"/>
                    <measurement group_id="O2" value="11.78" spread="2.679"/>
                    <measurement group_id="O3" value="20.93" spread="5.361"/>
                    <measurement group_id="O4" value="41.53" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL9+ (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.087"/>
                    <measurement group_id="O2" value="0.9" spread="0.245"/>
                    <measurement group_id="O3" value="0.13" spread="0.061"/>
                    <measurement group_id="O4" value="0.14" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.82" spread="0.019"/>
                    <measurement group_id="O2" value="23.29" spread="4.43"/>
                    <measurement group_id="O3" value="30.39" spread="5.391"/>
                    <measurement group_id="O4" value="40.4" spread="4.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL9+ (in CD4+CD25+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="4.497"/>
                    <measurement group_id="O2" value="0.59" spread="0.221"/>
                    <measurement group_id="O3" value="0.72" spread="0.213"/>
                    <measurement group_id="O4" value="1.3" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</title>
        <description>Peripheral blood chemokine cytokine levels measured by flow cytometry in healthy controls at baseline and in RRMS patients between visits during fingolimod treatment</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <population>Intent to treat. Data analyzed in RRMS patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy volunteers had only Visit 1 (day 0) when serum and whole blood samples were taken.</description>
          </group>
          <group group_id="O2">
            <title>Visit 1</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 1</description>
          </group>
          <group group_id="O3">
            <title>Visit 2</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 2</description>
          </group>
          <group group_id="O4">
            <title>Visit 3</title>
            <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients</title>
          <description>Peripheral blood chemokine cytokine levels measured by flow cytometry in healthy controls at baseline and in RRMS patients between visits during fingolimod treatment</description>
          <population>Intent to treat. Data analyzed in RRMS patients.</population>
          <units>percent of cell count</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.52" spread="1.494"/>
                    <measurement group_id="O2" value="71.92" spread="1.134"/>
                    <measurement group_id="O3" value="57.61" spread="2.401"/>
                    <measurement group_id="O4" value="59.29" spread="2.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="0.018"/>
                    <measurement group_id="O2" value="13.72" spread="1.336"/>
                    <measurement group_id="O3" value="6.13" spread="0.847"/>
                    <measurement group_id="O4" value="5.14" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.427" spread="1.328"/>
                    <measurement group_id="O2" value="10.17" spread="1.169"/>
                    <measurement group_id="O3" value="34.48" spread="2.758"/>
                    <measurement group_id="O4" value="33.91" spread="2.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NKT %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.65" spread="0.855"/>
                    <measurement group_id="O2" value="5.19" spread="0.766"/>
                    <measurement group_id="O3" value="15.55" spread="1.726"/>
                    <measurement group_id="O4" value="17.66" spread="1.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hi CD16CD56 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.183"/>
                    <measurement group_id="O2" value="0.93" spread="0.145"/>
                    <measurement group_id="O3" value="5.29" spread="1.296"/>
                    <measurement group_id="O4" value="6.20" spread="1.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+IL4+ % (in CD8+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="3.74"/>
                    <measurement group_id="O2" value="1.87" spread="0.538"/>
                    <measurement group_id="O3" value="3.13" spread="0.964"/>
                    <measurement group_id="O4" value="1.91" spread="1.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Visit until 30 days after Last Patient Last Visit) up to approximately 2 years.</time_frame>
      <desc>Only patients who received at least one dose of the investigational drug (N=66) were included in the data set used for safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fingolimod 0.5 mg</title>
          <description>Relapsing-remitting multiple sclerosis (RRMS) patients were treated with fingolimod 0.5 mg capsule od.</description>
        </group>
        <group group_id="E2">
          <title>All Patients</title>
          <description>All patients in the trial</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email.@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

